Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer. The ACET news feed on Stock Titan aggregates company-issued updates, SEC-linked announcements, and other coverage related to Adicet’s clinical programs, capital markets activity, and regulatory interactions.
Investors and followers of Adicet Bio can use this page to review news on its lead program, prulacabtagene leucel (prula-cel, formerly ADI-001), an investigational allogeneic gamma delta CAR T therapy targeting B cells via an anti-CD20 CAR. Company releases have highlighted Phase 1 data in lupus nephritis and systemic lupus erythematosus, enrollment across additional autoimmune indications such as systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA associated vasculitis and treatment-refractory rheumatoid arthritis, and regulatory designations including Fast Track status for several of these conditions.
The ACET news stream also reflects Adicet’s oncology work, including updates on ADI-212, a next-generation, gene-edited and armored gamma delta CAR T candidate targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer. Preclinical data presentations, plans for regulatory filings, and development timelines are typically communicated through press releases and associated 8-K filings.
Beyond clinical and scientific developments, Adicet Bio’s news includes information on registered direct offerings of common stock and pre-funded warrants, reverse stock split decisions, Nasdaq listing status notices, workforce and pipeline prioritization actions, and participation in healthcare conferences. By reviewing this curated ACET news page, readers can follow how Adicet reports progress in its autoimmune and oncology pipelines, how it manages its capital structure, and how key milestones are communicated through official channels.
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. Chen Schor, the company's President and CEO, will engage in a fireside chat during the conference, which is scheduled for February 5-6, 2025, in New York.
The presentation is set for Wednesday, February 5, 2025, at 2:00 p.m. ET. Interested parties can access the live audio webcast through the Investors section of Adicet Bio's website. A replay of the presentation will remain available for 30 days following the event.
Adicet Bio (NASDAQ: ACET) provided updates on its clinical programs and 2025 milestones. The company is advancing a Phase 1 trial of ADI-001 across six autoimmune diseases, with preliminary data in lupus nephritis expected in 1H25 and other cohorts in 2H25. Patient enrollment for various conditions including systemic lupus erythematosus and systemic sclerosis is set to begin in Q1 2025.
The company has also dosed its first patient in the Phase 1 trial of ADI-270 for renal cell carcinoma, marking the first gamma delta CAR T cell therapy in clinical development for solid tumors. Preliminary data is expected in 1H25. Both ADI-001 and ADI-270 have received FDA Fast Track Designation for their respective indications.
Clinical biomarker data from the Phase 1 GLEAN trial demonstrated ADI-001's robust tissue trafficking and complete CD19+ B cell depletion in secondary lymphoid tissue, supporting its potential as an off-the-shelf treatment option.
Adicet Bio (Nasdaq: ACET) announced an inducement grant awarded on December 31, 2024. The company granted one new employee non-qualified stock options to purchase 9,000 shares of common stock at an exercise price of $0.96 per share. The vesting schedule includes 25% after one year, with the remaining 75% vesting monthly over three years, completing full vesting on the fourth anniversary. The grant was made under Adicet's 2022 Inducement Plan, approved outside the stockholder-approved equity incentive plans, and authorized by the compensation committee as a material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company, has dosed the first patient in its Phase 1 clinical trial of ADI-270 for metastatic/advanced clear cell renal cell carcinoma (ccRCC), marking a significant milestone. ADI-270, an allogeneic gamma delta T cell therapy, aims to address the high unmet need for effective treatments in ccRCC, the most common type of kidney cancer. Preclinical data suggest ADI-270 has significant tumor infiltration capabilities, resistance to the immunosuppressive tumor microenvironment, and potent activity via CAR and innate-mediated targeting. Preliminary clinical data from the trial are expected in the first half of 2025.
Adicet Bio (NASDAQ: ACET) has appointed Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the clinical development strategy for Adicet's autoimmune and oncology pipeline. She brings over 20 years of experience in clinical development across oncology and autoimmune diseases, from early-phase trials to global approvals.
The company reports significant momentum in clinical trial enrollment for both ADI-001 and ADI-270 programs, with increasing site activations and patient enrollment. Dr. Maltzman succeeds Dr. Francesco Galimi, who completed his tenure this month. Prior to joining Adicet, Dr. Maltzman served as Chief Medical Officer at IconOVir Bio and held leadership positions at Roche/Genentech, where she oversaw the successful registration of Tecentriq+Avastin® combination therapy.
Adicet Bio (Nasdaq: ACET) announced an inducement grant awarded on November 29, 2024. The company granted one new employee non-qualified stock options to purchase 6,000 shares at an exercise price of $1.13 per share. The shares will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following three years. The grant was made under Adicet's 2022 Inducement Plan and approved by the compensation committee as a material inducement for employment in accordance with Nasdaq Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) has initiated enrollment for a Phase 1 clinical trial of ADI-270, their gamma delta CAR T cell therapy targeting metastatic/advanced clear cell renal cell carcinoma (ccRCC). This marks the first gamma delta CAR T cell therapy aimed at treating solid tumors. The company's ADI-270 is an armored allogeneic 'off the shelf' gamma delta 1 CAR T cell therapy targeting CD70 positive cancers. Preliminary Phase 1 clinical data is expected in the first half of 2025. Recent preclinical data presented at the ASGCT conference showed ADI-270's potential for significant tumor infiltration, resistance to immunosuppressive tumor microenvironment, and potent activity.
Adicet Bio (NASDAQ: ACET) has dosed its first lupus nephritis patient in the Phase 1 clinical trial of ADI-001 for autoimmune diseases. The company expects to share preliminary clinical data in 1H25. Additional patient enrollment for systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, and stiff person syndrome is planned for 1Q25, with ANCA-associated vasculitis enrollment expected in 2H25. The FDA has granted Fast Track Designation to ADI-001 for relapsed/refractory class III or IV lupus nephritis, and cleared the IND amendment for stiff person syndrome and idiopathic inflammatory myopathy treatment.
Adicet Bio (NASDAQ: ACET) presented clinical biomarker data for ADI-001, their off-the-shelf gamma delta CAR T cell therapy, at ACR Convergence 2024. The data showed robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue, with CAR T cell activation levels of 27-64% at the 1E9 dose. The company is advancing ADI-001 in a basket study across six autoimmune indications, including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, and ANCA-associated vasculitis.
Adicet Bio expanded its ADI-001 Phase 1 clinical trial to include six autoimmune disease indications, with preliminary lupus nephritis data expected in 1H25. The company reported Q3 2024 financial results with a net loss of $30.5 million ($0.34 per share). R&D expenses were $26.3 million, while G&A expenses reached $6.9 million. The company maintains a strong financial position with $202.1 million in cash and equivalents, expected to fund operations into 2H26. FDA granted Fast Track Designation for ADI-270 in metastatic/advanced clear cell renal cell carcinoma.